-
公开(公告)号：US20200069740A1
公开(公告)日：2020-03-05
申请号：US16491974
申请日：2018-03-08
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Hikari Hasegawa , Masayo Yumoto , Yoshifumi Ikeyama , Hiroyuki Nishida , Tomohiro Tsuda , Eiko Uno , Kazuma Suda , Mihoko Yoshino , Xuan Trung Ngo
IPC: A61K35/28
Abstract: The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition containing such mesenchymal stem cells. The present invention is a therapeutic agent for fibrosis that contains ROR1-positive mesenchymal stem cells and/or a culture supernatant thereof and that is for preventing or treating a disease associated with fibrosis. The mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive and are preferably derived from the umbilical cord or fat. In addition, the abovementioned disease associated with fibrosis is preferably a liver disease, a lung disease, a kidney disease, or a heart disease.
-
Patent Agency Ranking
公开(公告)号：US20190117701A1
公开(公告)日：2019-04-25
申请号：US16096973
申请日：2017-04-27
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yoshifumi Ikeyama , Eiko Uno , Masayo Yumoto , Mihoko Yoshino , Xuan Trung Ngo , Hiroyuki Nishida , Akiko Uetani
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.
-
公开(公告)号：US11707488B2
公开(公告)日：2023-07-25
申请号：US15755859
申请日：2016-08-29
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yoshifumi Ikeyama , Hiroyuki Nishida , Tomohiro Tsuda , Eiko Uno , Masayo Yumoto , Kazuma Suda , Mihoko Yoshino , Xuan Trung Ngo
IPC: A61K35/28 , C12N5/0775
CPC classification number: A61K35/28 , C12N5/0662 , C12N2501/998 , C12N2510/00 , Y02A50/30
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
-
公开(公告)号：US11179420B2
公开(公告)日：2021-11-23
申请号：US16096973
申请日：2017-04-27
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yoshifumi Ikeyama , Eiko Uno , Masayo Yumoto , Mihoko Yoshino , Xuan Trung Ngo , Hiroyuki Nishida , Akiko Uetani
IPC: C12N5/0775 , A61K35/28 , A61P29/00
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.
-
公开(公告)号：US20200171092A1
公开(公告)日：2020-06-04
申请号：US16620655
申请日：2018-05-08
Applicant: OSAKA UNIVERSITY , ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yoshiki Sawa , Shigeru Miyagawa , Daisuke Kajita , Hayato Kurata , Kotoe Tamada , Hiroyuki Nishida
Abstract: The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients. The present invention is a therapeutic agent for dilated cardiomyopathy comprising at least one selected from the group consisting of mesenchymal stem cell and microparticles derived from the mesenchymal stem cell. It is preferable that the mesenchymal stem cell is a cell having the ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.
-
公开(公告)号：US20180333436A1
公开(公告)日：2018-11-22
申请号：US15755859
申请日：2016-08-29
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yoshifumi Ikeyama , Hiroyuki Nishida , Tomohiro Tsuda , Eiko Uno , Masayo Yumoto , Kazuma Suda , Mihoko Yoshino , Xuan Trung Ngo
IPC: A61K35/28 , C12N5/0775
CPC classification number: A61K35/28 , C12N5/0662 , C12N2501/998 , C12N2510/00 , Y02A50/411
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
-
-
-
-
-
Search Results
6
records
(took 0.016 seconds)
